Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).

被引：0
|
作者：
Lee, Jeeyun
Kim, Seung Tae
Smith, Simon
Mortimer, Peter G.
Loembe, Bienvenu
Hong, Jung
Kozarewa, Iwanka
Pierce, Andrew
Dean, Emma
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] AstraZeneca Phaemaceut, Alderley Pk, England
[4] AstraZeneca, IMED Biotech Unit, Oncol, Cambridge, England
[5] AstraZeneca, Royston, England
[6] AstraZeneca, Cambridge, England
[7] Univ Manchester, Manchester, Lancs, England
[8] Christie NHS Fdn Trust, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3503
引用
收藏
页数：2
相关论文
共 21 条
  • [1] Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
    Kim, Seung Tae
    Smith, Simon A.
    Mortimer, Peter
    Loembe, Arsene-Bienvenu
    Cho, Heejin
    Kim, Kyoung-Mee
    Smith, Claire
    Willis, Sophie
    Irurzun-Arana, Itziar
    Berges, Alienor
    Hong, Jung Yong
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Kozarewa, Iwanka
    Pierce, Andrew J.
    Dean, Emma
    Lee, Jeeyun
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4700 - 4709
  • [2] Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study
    Geva, Ravit
    Lopez, Juanita
    Danson, Sarah
    Joensuu, Heikki
    Peer, Avivit
    Harris, Samuel J.
    Souza, Fabricio
    Pereira, Kaline M. C.
    Perets, Ruth
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1092 - 1101
  • [3] Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study
    Ravit Geva
    Juanita Lopez
    Sarah Danson
    Heikki Joensuu
    Avivit Peer
    Samuel J. Harris
    Fabricio Souza
    Kaline M. C. Pereira
    Ruth Perets
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1092 - 1101
  • [4] A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).
    Lim, Emerson A.
    Bauer, Todd Michael
    Patel, Manish R.
    Falchook, Gerald Steven
    Karlix, Janet L.
    Choe, Jennifer Hsing
    George, Daniel J.
    Mugundu, Ganesh M.
    Pilling, Elizabeth
    Chen, Huifang
    Linghu, Bolan
    McGrath, Lara
    Shao, Wenlin
    Merchant, Melinda S.
    Sidders, Ben
    Sachsenmeier, Kris F.
    Pouliot, Gayle Pageau
    Drake, Charles G.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study
    Kenjiro Aogi
    Norikazu Masuda
    Shinji Ohno
    Takashi Oda
    Hiroji Iwata
    Masahiro Kashiwaba
    Yasuhiro Fujiwara
    Shunji Kamigaki
    Yoshinori Ito
    Takayuki Ueno
    Shigemitsu Takashima
    Breast Cancer Research and Treatment, 2011, 129
  • [6] First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study
    Aogi, Kenjiro
    Masuda, Norikazu
    Ohno, Shinji
    Oda, Takashi
    Iwata, Hiroji
    Kashiwaba, Masahiro
    Fujiwara, Yasuhiro
    Kamigaki, Shunji
    Ito, Yoshinori
    Ueno, Takayuki
    Takashima, Shigemitsu
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (03) : 829 - 838
  • [7] Radium-223 in Combination with Paclitaxel in Cancer Patients wiith Bone Metastases: Safety Results from an Open-Label, Multicenter Phase 1b Study
    Lopez, J. S.
    Perets, R.
    Danson, S.
    Joensuu, H.
    Peer, A.
    Harris, S. J.
    Souza, F.
    Ploeger, B.
    Pereira, K. M. C.
    Geva, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S132 - S133
  • [8] Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    Slovin, S. F.
    Higano, C. S.
    Hamid, O.
    Tejwani, S.
    Harzstark, A.
    Alumkal, J. J.
    Scher, H. I.
    Chin, K.
    Gagnier, P.
    McHenry, M. B.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1813 - 1821
  • [9] Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study
    Iyer, Swaminathan P.
    Huen, Auris
    Ai, Weiyun Z.
    Jagadeesh, Deepa
    Lechowicz, Mary J.
    Okada, Craig
    Feldman, Tatyana A.
    Ghione, Paola
    Alderuccio, Juan P.
    Champion, Rebecca
    Kim, Seo-Hyun
    Mohrbacher, Ann
    Routhu, Kasi, V
    Barde, Prajak
    Nair, Ajit M.
    Haverkos, Bradley M.
    HAEMATOLOGICA, 2024, 109 (01) : 209 - 219
  • [10] Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer
    Goldman, Jonathan W.
    Waterhouse, David M.
    George, Ben
    O'Dwyer, Peter J.
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal U.
    Ong, Teng Jin
    Kelly, Karen
    FRONTIERS IN ONCOLOGY, 2019, 9
123